Published in J Cancer Res Clin Oncol on July 30, 2003
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol (2015) 2.07
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol (2007) 1.18
HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15
Development of therapeutic HPV vaccines. Lancet Oncol (2009) 1.04
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96
HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol (2013) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res (2015) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86
Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother (2016) 0.82
Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res (2009) 0.81
A simple in vitro method for evaluating dendritic cell-based vaccinations. Onco Targets Ther (2014) 0.78
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. Mol Cancer (2006) 0.77
Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma. J Exp Clin Cancer Res (2010) 0.77
DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin Exp Vaccine Res (2013) 0.76
Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. J Transl Med (2014) 0.76
Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology (Williston Park) (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol (1989) 8.68
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods (1996) 4.87
Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer (1993) 3.13
Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1990) 2.89
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59
Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med (1997) 2.33
A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods (2001) 2.15
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res (1988) 1.89
Papillomaviruses in human cancers. Proc Assoc Am Physicians (2000) 1.84
Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol (1997) 1.57
Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer (1992) 1.33
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother (2000) 1.09
Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res (1996) 1.08
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer (1994) 1.03
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother (2002) 1.03
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol (2001) 1.01
Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther (2001) 0.98
Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet (2000) 0.97
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 0.95
The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res (2001) 0.94
Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. Int J Cancer (2002) 0.91
Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer (2002) 0.91
Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med (2002) 0.89
Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer (1994) 0.89
Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol (2003) 0.85
Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol (1994) 0.83
HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer (2001) 0.83
Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. Gynecol Oncol (1999) 0.81
Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Cancer Gene Ther (1998) 0.79
Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma. Anticancer Res (1997) 0.75
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol (2008) 4.33
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Clinical relevance of objectifying colposcopy. Arch Gynecol Obstet (2014) 2.03
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87
Evaluation of the VITOM in digital high-definition video exocolposcopy. J Low Genit Tract Dis (2011) 1.87
Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83
A new approach to preserve fertility by using a coated nitinol stent in a patient with recurrent cervical stenosis. Fertil Steril (2006) 1.78
Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol (2008) 1.77
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol (2003) 1.70
Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol (2005) 1.68
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem (2008) 1.61
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res (2012) 1.49
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
New paradigm for prevention of cervical cancer. Eur J Obstet Gynecol Reprod Biol (2006) 1.48
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol (2009) 1.48
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype. Infect Immun (2008) 1.45
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44
Non-random integration of the HPV genome in cervical cancer. PLoS One (2012) 1.43
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer (2014) 1.41
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer (2004) 1.40
Cyclodimerization of an oxoboryl complex induced by trans ligand abstraction. Angew Chem Int Ed Engl (2010) 1.39
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res (2008) 1.38
Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein. Structure (2011) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35
Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res (2009) 1.33
Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol (2005) 1.32
The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res (2008) 1.30
Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res (2010) 1.30
Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer (2008) 1.29
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Helicobacter pylori multiplex serology. Helicobacter (2009) 1.29
Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol (2005) 1.27
Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol (2012) 1.27
Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev (2011) 1.26
Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol (2006) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.22
Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J Biol Chem (2001) 1.22
Ubiquitin protein ligase Nedd4 binds to connexin43 by a phosphorylation-modulated process. J Cell Sci (2006) 1.21
Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas. PLoS One (2013) 1.19